期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
膀胱癌特异性核基质蛋白(BLCAs)与膀胱癌
1
作者 李显文 《国外医学(泌尿系统分册)》 2002年第4期208-210,共3页
寻找早期诊断膀胱癌的无创性、简便而有高敏感度、高特异度的新瘤标有着重要的临床意义。本文对膀胱癌新瘤标膀胱癌特异性核基质蛋白BLCAs的研究现状、进展进行了系统的回顾 ,提出尿膀胱癌特异性核基质蛋白 4(BLCA 4)
关键词 膀胱癌 膀胱癌特异性核基质蛋白 blcas
暂未订购
Puerarin modulation of CENPA affects downstream PLK1 and CCNB1 expression to inhibit bladder cancer cell proliferation
2
作者 Hao Xu Wen Gao +7 位作者 Deng Pan Yu-Yang Ma Ruo-Ran Zhang Yong-Li Cao Yu-Chuan Zhou Ming-Yu Xu Pei-Yong Zhang Kun Pang 《Traditional Medicine Research》 2024年第9期32-41,共10页
Background:The treatment alternatives for bladder cancer(BLCA),the 10th most prevalent cancer in the world,need to be further investigated,and many active substances like Puerarin in herbal medicine were found to be e... Background:The treatment alternatives for bladder cancer(BLCA),the 10th most prevalent cancer in the world,need to be further investigated,and many active substances like Puerarin in herbal medicine were found to be effective in treating BLCA.The purpose of this study was to investigate the potential treating mechanisms of Puerarin on BLCA.Methods:The cell counting kit 8 assay and flow cytometry were performed to confirm Puerarin’s ability to suppress BLCA.The differentially expressed proteins(DEPs)were obtained by Tandem Mass Tags technology and functional enrichment analysis performed by R studio.The most enriched pathways were selected for study and the DEPs were screened out.Protein-protein interaction network maps were created using String and Cytoscape and key proteins,which will be analyzed for survival,expression,and upstream transcription factor prediction,were screened out using the cytoHubba plugin.CHEA3 was used to obtain upstream transcription factor validated by molecular docking and western blotting experiments.Results:Cell counting kit 8 showed that Puerarin inhibited BLCA cells,with 50%inhibitory concentration of 218μmol/L in T24 and 198μmol/L in 5637.Flow cytometry reveals that Puerarin blocks T24 and 5637 cells in G1 phase.1,385 DEPs were obtained and the enrichment analysis revealed that cell cycle and DNA replication were the two main areas in which DEPs were enriched.Cyclin-B-cyclin dependent kinase 1(CDK1),cyclin B1(CCNB1),and polo-like kinase 1(PLK1)were identified as key proteins,and their upstream transcription factor was predicted to be centromere protein A(CENPA).Puerarin’s binding energy to CENPA was determined by molecular docking to be−6.3 kcal/mol,indicating a strong binding interaction.Western blot showed that Puerarin significantly reduced the expression of CENPA.Conclusion:We hypothesize that Puerarin may inhibit the proliferation of bladder cancer cells by inhibiting CENPA expression to regulate PLK1 and CCNB1 expression,thereby affecting cell cycle. 展开更多
关键词 PUERARIN BLCA Tandem Mass Tags cell cycle
暂未订购
术前尿液BLCA-4及IL-8水平与膀胱癌临床病理特征的关系及意义 被引量:6
3
作者 杨大富 陆荣森 +2 位作者 廖俊 梁华良 黄芳伟 《河北医学》 CAS 2015年第6期884-887,共4页
目的:探讨术前尿液BLCA-4及IL-8水平与膀胱癌病理特征的关系并确定其在临床诊断上的意义。方法:采用酶联免疫反应原理分别检测膀胱癌组患者、正常对照组和高危性膀胱癌人群中术前尿液中BLCA-4和IL-8水平,分析研究他们与膀胱癌临床病理... 目的:探讨术前尿液BLCA-4及IL-8水平与膀胱癌病理特征的关系并确定其在临床诊断上的意义。方法:采用酶联免疫反应原理分别检测膀胱癌组患者、正常对照组和高危性膀胱癌人群中术前尿液中BLCA-4和IL-8水平,分析研究他们与膀胱癌临床病理特征的关系。结果:实验测得BLCA-4水平的Cutoff值为14.0 A/μg.protein,正常对照组尿中BLCA-4含量为2.7±5.8 A/μg.Protein;高危性膀胱癌组BLCA-4含量为9.1±18.7 A/μg.protein,均低于实验的Cut-off值,但高危性膀胱癌组明显高于正常对照组(P<0.01);而膀胱癌组患者尿中BLCA-4含量为45.3±69.2 A/μg.protein;显著高于正常对照组和高危性膀胱癌组(P<0.001)。与正常对照组相比,术前尿液中IL-8水平在高危性膀胱癌组和膀胱癌组均显著性上升,统计学差异分别为P<0.01,P<0.001。膀胱癌组患者术前尿液中BLCA-4和IL-8水平均与年龄、性别、肿瘤单发还是多发,初发还是复发没有显著统计学差异(P均>0.05),而与肿瘤的病理分期和分级有显著统计学差异(P<0.05)。结论:术前尿液BLCA-4及IL-8水平可能成为膀胱癌肿瘤诊断标志物,为临床早期诊断和病理特征判断提供依据。 展开更多
关键词 膀胱癌特异性核基质蛋白-4( BLCA -4) 白细胞介素-8( IL-8) 膀胱癌 病理特征
暂未订购
TIA1在膀胱癌中的表达及对膀胱癌发生发展和预后的影响 被引量:1
4
作者 胡彬 袁东波 +11 位作者 宋具昆 陈伟明 王蔚 刘恒 苏浩 张帆 张畅 杨科 钱成 何虎 杨萌 朱建国 《中华腔镜泌尿外科杂志(电子版)》 2021年第3期203-208,共6页
目的探讨T淋巴细胞内抗原1(TIA1)基因在膀胱癌中的表达情况及对膀胱癌发生发展和生存预后的影响。方法基于TCGA数据库,使用Kaplan-Meier曲线和ROC曲线分析TIA1基因表达与膀胱癌生存预后的关系和诊断价值。采用秩和检验分析TIA1表达与临... 目的探讨T淋巴细胞内抗原1(TIA1)基因在膀胱癌中的表达情况及对膀胱癌发生发展和生存预后的影响。方法基于TCGA数据库,使用Kaplan-Meier曲线和ROC曲线分析TIA1基因表达与膀胱癌生存预后的关系和诊断价值。采用秩和检验分析TIA1表达与临床特征的关联。单因素和多因素Cox回归分析TIA1及临床特征预测膀胱癌(BLCA)患者预后的可能,并构建诺模图预测BLCA患者的无进展生存率。基因集富集分析(GSEA)用于探索TIA1在膀胱癌中的潜在作用机制。免疫蛋白印迹实验(WB)验证TIA1蛋白在膀胱癌和癌旁组织中的表达差异。结果生存分析表明TAI1高表达组的总生存率(P=0.00135)、无进展生存率(P=0.00154)和无疾病生存率(P=0.00116)均高于低表达组。TIA1在低龄组(≤60岁)中表达明显高于高龄组(P=0.007),解剖分期和T分期越高,TIA1表达越低(P<0.01)。COX回归分析表明TIA1(P=0.047)、年龄(P<0.001)、解剖分期(P<0.001)是BLCA患者的独立预后因素。诺模图的C指数等于0.661(0.619~0.704),提示该模型具有较好的预测能力。GSEA分析表明TIA1富集在"KEGG-Bladder cancer"和"KEGG-natural killer cell-mediated cytotoxicity"相关的通路。WB实验证明TIA1蛋白在BLCA组织中的表达也低于癌旁组织。结论TIA1基因在膀胱癌组织中表达下调,可能是BLCA发生发展的独立预后因素,用TIA1基因表达水平、年龄、临床分期共同构建的预后模型对BLCA患者无进展生存有较好的预测能力。 展开更多
关键词 膀胱癌(BLCA) T淋巴细胞内抗原1(TIA1) TCGA数据库 生物信息学
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部